Managing chromoblastomycosis with acitretin plus imiquimod: A case report on the improvement of cutaneous lesions and reduction of the treatment time

Chromoblastomycosis (CBM) is an infectious disease caused by fungi that is prevalent in tropical and subtropical countries. Besides few therapeutic options, the classical treatment of CBM needs to be administrated for a long period of time, and unfortunately some patients do not show improvement of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2021-10, Vol.48 (10), p.1612-1615
Main Authors: Belda, Walter, Casolato, Ana Thereza Stradioto, Luppi, Juliana Bronzato, Passero, Luiz Felipe Domingues
Format: Article
Language:English
Subjects:
acitretin
Acitretin - therapeutic use
Antiviral drugs
Case reports
chromoblastomycosis
Chromoblastomycosis - drug therapy
Chromomycosis
Drug therapy
Drug Therapy, Combination
Fungal infections
Humans
Imiquimod
Imiquimod - therapeutic use
Infectious diseases
lesion evolution
Lesions
Patients
treatment
Vitamin A
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chromoblastomycosis (CBM) is an infectious disease caused by fungi that is prevalent in tropical and subtropical countries. Besides few therapeutic options, the classical treatment of CBM needs to be administrated for a long period of time, and unfortunately some patients do not show improvement of the lesions. Thus, it becomes urgent to develop new strategies for the treatment of CBM. This work reports a successful treatment, performed with the combination of oral acitretin (50 mg/kg, once a day) plus topical imiquimod (50 mg/g, five times per week) for 5 months in a patient with CBM. A significant improvement of the lesions was observed in the 1st month, and in the 5th a complete regression of lesions was recorded. Changes in the biochemical parameters were not observed. These data suggest that the combination of acitretin and imiquimod may be effective at treating CBM.
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.16101